Review

The term "carcinoid" is a misnomer: the evidence based on local invasion

Jun Soga

Address: Niigata Seiryo University, Niigata, Japan
Email: Jun Soga - soga-j@ginzado.ne.jp

Abstract

Background: Since Oberndorfer proposed the term "carcinoid" in 1907, over 100 years have passed. This attractive term was initially proposed for 6 cases of his own experience with 12 submucosal lesions in the small intestine.

Oberndorfer summarized the characteristic features of these lesions as follows: (1) small in size and often multiple, (2) histologically undifferentiated with a suggestion of gland-formation, (3) well-defined without any tendency to infiltrate the surroundings, (4) no metastases, and (5) apparently slow-growing reaching no significant size with a seemingly harmless nature.

Review: This article stresses the malignant nature of "carcinoid" on the basis of local invasion prior to metastases in the first two sessions, (1) with Oberndorfer's original diagram, and (2) with an experimental observation on extraglandular microcacinoid in a form of "budding".

Next, (3) a statistical comparison between a carcinoid group and a non-carcinoid ordinary carcinoma group is introduced on metastasis rates at an early stage with two prescribed factors of the depth of invasion restricted within the submucosa (sm-lesion) and a small tumor size category of 1 cm to 2 cm: the carcinoid group exhibited metastasis rates higher than those in the ordinary carcinoma group when calculated in the stomach and rectum.

In the author's experience, "carcinoids" are malignant not only in the gastrointestinal tract but also in the other sites on the basis of local invasion.

Lastly, (4) discussion on the terminology of "carcinoid" as a misnomer is carried out.

Adequate terms referring to the entity of this malignant tumor group are discussed. One of the most adequate and brief terms for "carcinoid" that is included now in neuroendocrine tumor group would be "endocrinocarcinoma" as per the author's proposal, followed by NEC (neuroendocrinocarcinoma) or GEC (gut endocrinocarcinoma).

Conclusion: The term "carcinoid" is a misnomer that can be confirmed on the basis of local invasion prior to metastases. "No metastases without local invasion" is not of a negligible importance.
Background
Since Oberndorfer proposed the term "carcinoid" in 1907, over 100 years have passed. This attractive term was initially used for 6 cases of his own experience with 12 submucosal lesions in the small intestine.

Oberndorfer summarized the characteristic features of these lesions as follows: (1) small in size and often multiple, (2) histologically undifferentiated with a suggestion of gland-formation, (3) well-defined without any tendency to infiltrate the surroundings, (4) no metastases, and (5) apparently slow-growing reaching no significant size with a seemingly harmless nature.

Review
Introduction
In this short article, the malignancy of carcinoids is stressed on the basis of local invasion prior to metastases in the first two sessions.

A statistical comparison of metastasis rates between a carcinoid group and a non-carcinoid ordinary carcinoma group is introduced at an early stage with two prescribed factors of the depth of invasion and a small tumor size category.

Finally, the terminology of carcinoid as a misnomer is discussed.

Reevaluation of Oberndorfer's original diagram of "submucosal nodule"
Characteristic features of lesions described by Oberndorfer are well reflected in a beautiful and precise diagram in Fig. 1 in his article [1], indicating a lesion involving a small portion of the mucosa and a large space of the submucosa, the latter seemingly well-defined but without encapsulation.

The findings of this lesion indicate, however, apparent malignancy of the tumor with the small original site in the mucosa invading down continuously into the submucosa forming a larger submucosal nodule as a result. Thus, the lesion is a malignant epithelial tumor, namely a carcinoma, but not a "carcinoma-like" tumor of benign nature that was initially described as a carcinoid.

Extraglandular microcarcinoid in a form of "budding"
All gastrointestinal "carcinoids" are malignant at their very beginning, "budding" stage, of neoplastic formation.

The early developmental process of carcinoid formation may be hypothetically divided into three stages as shown in Table 1.

### Table 1: Microproliferation of argyrophil cells [2]

| Stage   | Description                |
|---------|----------------------------|
| I       | Hyperplastic: Intraglandular |
| II      | Preneoplastic: Intraglandular |
| III     | Neoplastic:                |
| IIIa    | Intraglandular             |
| IIIb    | Extraglandular ("budding": microinvasion) |

Extraglandular neoplastic formation starts with a form of "budding" (IIIB).

An observation on consecutive serial sections of the glandular stomach of an experimental animal clearly indicates that the extraglandular microproliferation of argyrophil cells (IIIB) is a malignant lesion as a "microcarcinoid" at its very beginning of neoplastic formation in a form of "budding" as indicated in Fig. 3A–C in the article [2]. Such a developmental process of invasion prior to metastases is thought to be identical to the process in other organs not only of the other sites of the gastrointestinal tract, but also in other sites including the extradigestive organs.

A comparison of metastasis rates in early stage: sm-lesions of carcinoids and ordinary carcinomas
Malignancy represented by metastasis rates in early stages with depth of invasion of the lesions restricted within the submucosa (sm-lesion) is discussed in a statistical comparison between two groups of carcinoid (n = 1158) and ordinary carcinoma (n = 1141) in Table 9 of the article [3].

In the stomach, the metastasis rates of the two groups of carcinoid versus ordinary carcinoma are calculated as 21.4% versus 3.1% in the size range category of 10.1 mm - 20.0 mm (p < 0.0001).

In the rectum, the metastasis rates of these two groups are described as 27.6% versus 10.0% in the same size category (p < 0.05), and as 32.4% versus 9.8% in the size range category over 10.1 mm as a whole (p < 0.0001). These results show that early stage carcinoids, with two prescribed factors of depth of invasion restricted within the submucosa and tumor size range of 1 cm to 2 cm, metastasize earlier than ordinary carcinomas with the identical description in both the stomach and rectum.

Terminology
The term "carcinoid" has been deprecated by several authors mostly based on the metastatic potentiality (Table 2), as unfortunate [4], misleading and unsafe [5], outmoded [6,7], archaic [8,9], confusing [10], and even a misnomer by some authors [3,11-15]. One of the most adequate and brief terms for "carcinoid" that is included now in the group of GEP-NETs (gastroenteropancreatic neuroendocrine tumors) or simply NETs [8,16,17] would be "endocrinocarcinoma" [18-21], followed by NEC (neuroendocrinocarcinoma) or GEC (gut endocrinocarcinoma).
On the other hand, since the term "carcinoid" has been so attractive and popularly used on a worldwide scale, and will be alive in the future for searching systems such as PubMed or Index Medicus, it would be very difficult and inconvenient to eliminate this term in a short period of time. Meanwhile this term and a newly accepted term, if decided, should be interchangeable with each other for the purpose of automated searching: for a concrete example, the new term with carcinoid in parentheses: [endocrinocarcinoma (carcinoid) ...].

Most important is that the term "carcinoid" should be used for a certain number of years, at least during the present generation of more or less 50 years, in the author's estimation, and be described without an adjective "benign" or "malignant" in recognition of the real entity of this particular malignant tumor group. Then, the necessity of the term "carcinoid" might be discussed by the next generation concerning its usefulness in automated searching for the literature.

No "benign" carcinoid without local invasion has been available up to this date either in the digestive organs or extradigestive sites in the author's experience.

Only complete serial sections of a seemingly encapsulated lesion could prove the benignity, if any, with definite confirmation for the absence of a break of the capsule by microinvasion or budding. This would be, however, practically impossible. The histologic patterns or classification [11,14] would be still well applicable to "endocrinocarcinoma" as an initial morphologic implication for diagnosis.

The adequate term should be globally and historically discussed in relation to the real entity of this tumor group, considering the evaluation of the Consensus Conference.

Changes in concepts of "carcinoid"
It is extraordinarily courageous to coin a new concept of tumor entity, as did Oberndorfer, a 31-year-old enthusiastic young scientist at that time in the year 1907 [1], and similarly to criticize a well-established and world-wide accepted concept introduced even in the textbooks. However, a change corrected on the basis of the truth is always required in science.

Conclusion
The term "carcinoid" is a misnomer: the malignancy of this tumor group can be confirmed on the basis of local invasion prior to metastases. "No metastases without local invasion" is not of a negligible importance.

The adequate term should be globally and historically discussed in relation to the real entity of this tumor group, considering the evaluation of the Consensus Conference.

Competing interests
The author has been retired from any institutional career for almost four years, and he has no competing interests of either a financial or a non-financial type in relation to this manuscript.

Author's information
Recipient: (1) IRPC Eminent Scientist of the Year 2004: World Scientists Forum International Awards in Surgery and Surgical Pathology, 2004.
(2) ENETS Life Achievement Award and (3) IPSEN Oberndorfer Prize, at the 5th ENETS in Paris, 2008.
IRPC: International Research Promoting Council.
ENETS: European Neuroendocrine Tumor Society.
IPSEN: Institut de Produits de Synthèse et d’Extraction Naturelle.

NET: Neuroendocrine Tumor/NEC: Neuroendocrine Carcinoma.

Acknowledgements
The author appreciates the editorial understandings of the Journal of Experimental & Clinical Cancer Research for having given him the opportunity to propose this review article. The author’s appreciation further extends to Mr. A. Suarez who made adjustments of English expressions in the manuscript.

References
1. Oberndorfer S. Karzinoides Tumoren des dünndarms. Frankf Z Pathol 1907, 1:426-432.
2. Soga J, Kohro T, Tazawa K, Kanahara H, Sano M, Sakashita T, Tajima K, Morooka H, Karaki Y: Argyrophil cell microneoplasia in Mas-
tomys' stomach – An observation on early carcinoid formation. J Natl Cancer Inst 1975, 55:1001-1006.
3. Soga J: Early-stage carcinoids of the gastrointestinal tract. An analysis of 1914 reported cases. Cancer 2005, 109:1587-1595.
4. Willis RA: Argentaffin carcinomata ("carcinoids") of the small intestine. Med J Aust 1940, 2:400-403.
5. Roberts TW: Argentaffin carcinoma arising in teratoma of ovary. Delaware State Med J 1958, 30:182-185.
6. Wick MR, Rosai J: Neuroendocrine neoplasms of the thymus. Pathol Res Pract 1988, 183:188-199.
7. Klemm KM, Moran CA: Primary neuroendocrine carcinomas of the thymus. Semin Diag Pathol 1999, 16:32-41.
8. Modlin IM, Sandor A: An analysis of 8305 cases of carcinoid tumor. Cancer 1997, 79:813-829.
9. Modlin IM, Kidd M, Latich I, Zukusoka MN, Shapiro MD: Current status of gastrointestinal carcinoids. Gastroenterology 2005, 128:1717-1751.
10. Andreas R, Mayordomo Jr, Cajal SR, Tres A: Cushing's syndrome associated to locally advanced thymic carcinoid tumor. Tumori 2002, 88:65-67.
11. Soga J: Carcinoids: Their changing concepts and a new histologic classification. In Gastro-Entero-Pancreatic System: A Cell-Biological approach Edited by: Fujita T. Scutgitz: George Thieme (Verlag); 1973:101-119.
12. Rowe LD, Jafek BW: Bronchial adenoma: A malignant misnomer. Laryngoscope 1979, 89:1991-1999.
13. Moertel CG: Karnofsky memorial lecture. An Odyssey in the land of small tumors. J Clin Oncol 1987, 5:1503-1522.
14. Soga J, Yakuwa Y, Osaka M: A classification of problems regarding gut endocrinomas (carcinoids and relevant neoplasms). J Exp Clin Cancer Res 1999, 18:5-12.
15. Soga J: Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases. J Exp Clin Cancer Res 2003, 22:517-530.
16. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltssas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A: Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008, 9:61-72.
17. Rindi G, Kloorpe G, Couvelard A, Kominotio P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B: TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007, 451:757-762.
18. Soga J: Endocrinocarcinoma (carcinoids and their variants) of the duodenum: an evaluation of 927 cases. J Exp Clin Cancer Res 2003, 22:349-363.
19. Soga J, Ferlito A, Rinaldo A: Endocrinocarcinomas (carcinoids and their variants) of the larynx: a comparative consideration with those of other sites. Oral Oncol 2004, 40:668-672.
20. Ferlito A, Rinaldo A: The spectrum of endocrinocarcinoma of the larynx. Oral Oncol 2005, 41:878-883.
21. Soga J: Gut-Pancreatic Endocrinomas – Endocrinocarcinomas: Carcinoids and their variant neoplasms. 3rd edition. Kokoko-Co. Ltd., Niigata; 2004.